Azenta buys SynPlexity, licenses Elegen in up to $71M DNA synthesis push
What's the deal? Azenta Life SciencesDealroom has a profile for this one. Try Dealroom → has acquired DNA assembly firm SynPlexityDealroom has a profile for this one. Try Dealroom → and secured an exclusive gene synthesis license from Elegen Corp., it disclosed in a Form 8-K on October 30, 2026. The company acquired all of SynPlexity's outstanding stock in a deal that closed October 28; terms were undisclosed.
Breaking down the terms: The Elegen agreements grant Azenta a royalty-free, exclusive license to make, sell, and distribute gene synthesis products globally for an initial five-year term. Total capital deployment is projected between roughly $32 million and $71 million, depending on equipment purchases and options.
Why both? SynPlexity specialises in large multiplexed gene libraries for drug discovery, therapeutics, and functional screening. Elegen brings patents in gene synthesis and cell-free cloning, plus proprietary consumables supplied under a separate master services agreement.
What's the endgame? Both moves aim to advance Azenta's DNA synthesis technology and expand its GENEWIZDealroom has a profile for this one. Try Dealroom → gene synthesis services and regional manufacturing capacity. Azenta can convert the Elegen license into a perpetual, irrevocable one by paying $25 million, exercisable 12 to 18 months after signing.
Elegen retains limited rights to supply its platform for internal research, existing customer contracts, and restricted evaluations. Should the license expire without conversion, it continues on a perpetual, fully paid, non-exclusive basis.
The signal: Azenta is consolidating DNA synthesis capabilities through acquisition and licensing rather than building alone — a bid to strengthen GENEWIZ as demand for synthetic genes rises across therapeutics and drug discovery. Full agreement details are due in its Form 10-Q for the quarter ending December 31, 2026.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
